1-1 of 1
bionics
Close
Save search
Sort by
Journal Articles

A 3-Arm Randomized Phase II Trial with Bendamustine/Rituximab Therapy in Untreated High Risk (HR) Follicular Lymphoma (FL): Bortezomib Induction or Novel IMiD ® Continuation (BIONIC) Study from the ECOG-ACRIN Cancer Research Group

Free
Andrew M Evens, DO,MSc, Fangxin Hong, PhD, Thomas M Habermann, MD, Ranjana H. Advani, MD, Randy D. Gascoyne, MD, Thomas E Witzig, MD, Andrew Quon, MD, Erik A. Ranheim, MD PhD, Puneet Cheema, MD, Philip Dy, MD, Timothy E. O'Brien, MD, Jane N. Winter, MD, Terrence Paul Cescon, Julie Chang, MD, Brad S Kahl, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 482.
https://doi.org/10.1182/blood.V130.Suppl_1.482.482
Published: 2017